New mRNA Vaccine Shows Promise in Treating Skin Cancer
新型mRNA疫苗在治療皮膚癌方面展現潛力
更新於: 2026年8月26日 上午12:45
A groundbreaking medical study has brought new hope to patients fighting melanoma.
一項開創性的醫學研究為對抗黑色素瘤的患者帶來了新希望。
A collaborative project between Moderna and Merck has successfully tested a personalized mRNA-based cancer vaccine, known as mRNA-4157, designed to prevent the recurrence of skin cancer.
Moderna與默克(Merck)攜手合作的一個計畫,成功測試了一種名為mRNA-4157的個性化mRNA癌症疫苗,旨在預防皮膚癌復發。
In a large Phase 3 clinical trial, researchers found that combining this vaccine with the immunotherapy drug Keytruda significantly lowered the chances of the cancer returning or spreading compared to using the drug alone.
在一項大型第三期臨床試驗中,研究人員發現,將此疫苗與免疫治療藥物Keytruda結合使用,與僅單獨使用該藥物相比,能顯著降低癌症復發或擴散的機率。
Unlike traditional vaccines that prevent infectious diseases, this treatment is highly personalized.
不同於預防傳染病的傳統疫苗,這種治療方法具有高度的個性化。
Scientists analyze the genetic code of a patient's specific tumor to create a custom vaccine.
科學家透過分析患者特定腫瘤的基因密碼,來製作客製化的疫苗。
While this treatment is still in the experimental stages, the results represent a historic milestone in oncology.
儘管這種治療仍處於實驗階段,但這些結果代表了腫瘤學上的一個歷史性里程碑。
